TransMedics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of TransMedics (TMDX) with an Outperform rating and $155 price target There is a misunderstanding among investors that the cost of TransMedics’ services are materially higher than competitive alternatives, but the firm’s analysis shows total costs are similar, despite materially better patient outcomes, the analyst tells investors. The firm cites the company’s “differentiated” end-to-end organ transplant offering and “impressive financial outlook” for its Outperform rating on TransMedics.